An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.

Active:	No
Cancer Type:	Colon/Rectal Cancer Unknown Primary	NCT ID:	NCT04660812
Trial Phases:	Phase I Phase II	Protocol IDs:	ARC-9 (primary) NCI-2021-02881 2020-005386-13
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Arcus Biosciences, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT04660812

Summary

This randomized phase 1b/2 open-label study will evaluate the antitumour activity and safety
of etrumadenant (AB928) treatment combinations in participants with metastatic colorectal
cancer.

Objectives

This is a multicenter, open-label Phase 1b/2 study in participants with metastatic colorectal
cancer that will assess the antitumour activity and safety of etrumadenant.

Approximately 250 participants will be enrolled to 1 of 3 cohorts:

Cohort A) etrumadenant + zimberelimab +mFOLFOX-6 +/-bevacizumab vs mFOLFOX-6 +/-bevacizumab

Cohort B) etrumadenant + zimberelimab +mFOLFOX-6 +/-bevacizumab vs regorafenib

Cohort C) chemotherapy-free combinations of etrumadenant + zimberelimab + other agents

The primary objective of this clinical study is to evaluate the safety of etrumadenant-based
combination therapy in participants with metastatic colorectal cancer.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.